Abstract
Multiple myeloma (MM) is a plasma cell-derived malignancy that stands for around 1.5% of newly discovered cancer cases. Despite constantly improving treatment methods, the disease is incurable with over 13,000 deaths in the US and over 30,000 in Europe. Recent studies suggest that extracellular vesicles (EVs) might play a significant role in the pathogenesis and evolution of MM. Further investigation of their role could prove to be beneficial in establishing new therapies and hence, improve the prognosis of MM patients. What is more, EVs might serve as novel markers in diagnosing and monitoring the disease. Great advancements concerning the position of EVs in the pathophysiology of MM have recently been shown in research and in this review, we would like to delve into the still expanding state of knowledge.
Funder
National Science Centre, Poland
Reference126 articles.
1. Pathobiology and Diagnosis of Multiple Myeloma;Semin. Oncol. Nurs.,2017
2. National Cancer Institute (2022, August 13). Surveillance, Epidemiology, and End Result Program, Available online: https://seer.cancer.gov/statfacts/html/mulmy.html.
3. Saltarella, I., Lamanuzzi, A., Apollonio, B., Desantis, V., Bartoli, G., Vacca, A., and Frassanito, M.A. (2021). Role of Extracellular Vesicle-Based Cell-to-Cell Communication in Multiple Myeloma Progression. Cells, 10.
4. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM);Leukemia,2020
5. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: A prospective study;Blood,2009
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献